How can LRRK2 kinase inhibitors be designed to avoid safety liabilities in non-neuronal tissues?

The abstract identifies that LRRK2 inhibition in non-neuronal tissues raises safety concerns, creating a therapeutic paradox since the protein is ubiquitously expressed. This represents a critical barrier to translating LRRK2 research into viable Parkinson’s treatments.

Gap type: open_question Source paper: LRRK2 and Parkinson’s Disease: From Lack of Structure to Gain of Function. (2017, Current protein & peptide science, PMID:26965688)

{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:42.894858+00:00”, “resolution_summary”: “Resolved by hypothesis h-d4ac0303f6: G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying lysosomal swelling gain. Supporting evidence includes debate sess_SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867_20260416-135352.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-d4ac0303f6”, “title”: “G2019S primarily raises baseline LRRK2 kinase activity rather than amplifying lysosomal swelling gain”, “score”: 0.263, “reason”: “6 token overlaps; entity overlap: lrrk2”, “analysis_id”: “SDA-2026-04-25-gapdebate-9180363b7c”, “target_gene”: “LRRK2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.79, “confidence_score”: 0.32, “status”: “proposed”, “pubmed_evidence_ids”: [“23066449”, “34125248”, “34686322”, “35580815”, “35907404”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867_20260416-135352”, “title”: “While the study establishes LRRK2 as a lysosomal swelling sensor and notes that lysosomal swelling occurs in LRRK2-linked diseases, it doesn’t directly test whether pathogenic LRRK2 mutations alter this volume-sensing function. This connection is crucial for understanding how LRRK2 mutations cause Parkinson’s disease and related disorders.\n\nGap type: open_question\nSource paper: Lysosomal swelling triggers LRRK2 activity. (2026, bioRxiv : the preprint server for biology, PMID:41427358)”, “score”: 0.484, “reason”: “9 token overlaps; entity overlap: lrrk2, pmid”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867”, “quality_score”: 0.85, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2_task_9aae8fc5”, “title”: “While the abstract identifies AQP4 as a ‘potential and promising target’ and mentions it could provide ‘new therapeutic alternatives,’ the specific approaches for therapeutic modulation of AQP4 function are not defined. This represents a critical translational gap for moving from mechanistic understanding to clinical intervention.\n\nGap type: open_question\nSource paper: Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. (2023, Neurobiol Dis, PMID:36796590)”, “score”: 0.431, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.428, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-145531-5c4e7b59_20260414-005547”, “title”: “The abstract reports extraordinary dopamine increases (>500-fold in drug-free patients) but provides no mechanistic explanation for how Atremorine achieves this effect. Understanding these mechanisms is critical for optimizing therapeutic applications and predicting safety profiles.\n\nGap type: unexplained_observation\nSource paper: Atremorine in Parkinson’s disease: From dopaminergic neuroprotection to pharmacogenomics. (2021, Med Res Rev, PMID:34106485)”, “score”: 0.408, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-145531-5c4e7b59”, “quality_score”: 0.67, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-06-gap-pubmed-20260406-041439-5f43216e_task_9aae8fc5”, “title”: “The abstract identifies dystrophic microglia as senescent cells in aged brains but doesn’t explain the underlying mechanisms. Understanding these pathways is critical since identifying factors that drive microglial aging could delay neurodegenerative disease onset.\n\nGap type: unexplained_observation\nSource paper: Beyond Activation: Characterizing Microglial Functional Phenotypes. (2021, Cells, PMID:34571885)”, “score”: 0.392, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-06-gap-pubmed-20260406-041439-5f43216e”, “quality_score”: 0.794, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}